QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

NCT05446883 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

498

Enrollment

INDUSTRY

Sponsor class

Conditions

METASTATIC CERVICAL CANCER

Interventions

DRUG: QL1706
DRUG: Placebo
DRUG: Paclitaxel injection
DRUG: Cisplatin/Carboplatin

Sponsor

Qilu Pharmaceutical Co., Ltd.